SK132498A3 - Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase - Google Patents

Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase Download PDF

Info

Publication number
SK132498A3
SK132498A3 SK1324-98A SK132498A SK132498A3 SK 132498 A3 SK132498 A3 SK 132498A3 SK 132498 A SK132498 A SK 132498A SK 132498 A3 SK132498 A3 SK 132498A3
Authority
SK
Slovakia
Prior art keywords
rel
pyrrol
methanesulfonyl
isopropyl
compound
Prior art date
Application number
SK1324-98A
Other languages
English (en)
Slovak (sk)
Inventor
Michael D Dowle
Harry Finch
Lee A Harrison
Graham G A Inglis
Martin R Johnson
Simon J F Macdonald
Pritom Shah
Robin A Smith
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9606508.1A external-priority patent/GB9606508D0/en
Priority claimed from GBGB9623001.6A external-priority patent/GB9623001D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of SK132498A3 publication Critical patent/SK132498A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
SK1324-98A 1996-03-28 1997-03-26 Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase SK132498A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9606508.1A GB9606508D0 (en) 1996-03-28 1996-03-28 Chemical componds
GBGB9623001.6A GB9623001D0 (en) 1996-11-05 1996-11-05 Chemical compounds
PCT/EP1997/001530 WO1997036903A1 (en) 1996-03-28 1997-03-26 Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase

Publications (1)

Publication Number Publication Date
SK132498A3 true SK132498A3 (en) 1999-08-06

Family

ID=26309008

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1324-98A SK132498A3 (en) 1996-03-28 1997-03-26 Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase

Country Status (30)

Country Link
US (3) US5994344A (enExample)
EP (1) EP0891362B1 (enExample)
JP (1) JP4118337B2 (enExample)
KR (1) KR20000005039A (enExample)
CN (1) CN1067075C (enExample)
AP (1) AP823A (enExample)
AR (1) AR006401A1 (enExample)
AT (1) ATE261969T1 (enExample)
AU (1) AU726649B2 (enExample)
BR (1) BR9708449A (enExample)
CA (1) CA2250209A1 (enExample)
CO (1) CO4790152A1 (enExample)
CZ (1) CZ309798A3 (enExample)
DE (1) DE69728139T2 (enExample)
DK (1) DK0891362T3 (enExample)
EA (1) EA001437B1 (enExample)
EE (1) EE9800335A (enExample)
ES (1) ES2217404T3 (enExample)
HU (1) HUP9900567A3 (enExample)
IL (1) IL125859A0 (enExample)
IS (1) IS4837A (enExample)
NO (1) NO984470L (enExample)
NZ (1) NZ331490A (enExample)
PE (1) PE55298A1 (enExample)
PL (1) PL329153A1 (enExample)
PT (1) PT891362E (enExample)
SK (1) SK132498A3 (enExample)
TR (1) TR199801935T2 (enExample)
WO (1) WO1997036903A1 (enExample)
YU (1) YU41198A (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9719189D0 (en) * 1997-09-09 1997-11-12 Glaxo Group Ltd New therapeutic method
GB9719187D0 (en) 1997-09-09 1997-11-12 Glaxo Group Ltd Compounds
PE107899A1 (es) * 1997-09-09 1999-11-17 Glaxo Group Ltd Derivados de pirrolopirrolona como inhibidores de elastasa leucocitaria
GB9719172D0 (en) 1997-09-09 1997-11-12 Glaxo Group Ltd Compounds
GB9821199D0 (en) * 1998-09-30 1998-11-25 Glaxo Group Ltd Chemical compounds
GB9905418D0 (en) * 1999-03-09 1999-05-05 Glaxo Group Ltd Process
AU2003216707A1 (en) * 2003-03-10 2004-09-30 Hetero Drugs Limited Amorphous clopidogrel hydrogen sulfate
JP4736043B2 (ja) 2003-03-14 2011-07-27 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤
AU2007351866C1 (en) * 2003-06-20 2013-07-25 Siga Technologies, Inc. Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
US8530509B2 (en) 2003-06-20 2013-09-10 Siga Technologies, Inc. Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
US7692037B2 (en) * 2004-09-02 2010-04-06 Eastman Chemical Company Optimized liquid-phase oxidation
GB2418427A (en) 2004-09-02 2006-03-29 Univ Cambridge Tech Ligands for G-protein coupled receptors
AU2005283326B2 (en) * 2004-09-13 2011-07-21 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
GB0512238D0 (en) * 2005-06-15 2005-07-27 Univ Cambridge Tech Anti-inflammatory agents
RU2008140144A (ru) 2006-03-10 2010-04-20 Оно Фармасьютикал Ко., Лтд. (Jp) Азотосодержащее гетероциклическое производное и фармацевтическое средство, включающее такое производное в качестве активного ингредиента
EP2231600B1 (en) 2007-11-16 2015-07-29 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
EP2231666B1 (en) 2007-12-12 2015-07-29 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
WO2009132136A1 (en) 2008-04-23 2009-10-29 Rigel Pharmaceuticals, Inc. Carboxamide compounds for the treatment of metabolic disorders
GEP20186885B (en) * 2012-12-18 2018-08-10 Chiesi Farma Spa Novel compounds
AU2020349353A1 (en) 2019-09-17 2022-04-14 Duke University Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease
HUE064089T2 (hu) 2020-04-16 2024-02-28 Mereo Biopharma 4 Ltd Alvelesztat neutrofil elasztáz inhibitort alkalmazó módszerek alfa-1-antitripszin hiány által közvetített légzõszervi megbetegedés kezelésére
AU2022373971A1 (en) 2021-10-20 2024-04-04 Mereo Biopharma 4 Limited Neutrophil elastase inhibitors for use in the treatment of fibrosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2932650A (en) * 1957-11-19 1960-04-12 Arthur C Cope 2-6-diazabicyclo (3. 3. 0) octanes
US4997950A (en) * 1989-04-20 1991-03-05 Richard Finbar Murphy Novel C-terminal gastrin antagonists
GB9211783D0 (en) * 1992-06-04 1992-07-15 Ici Plc Amide derivatives
GB9402680D0 (en) * 1994-02-11 1994-04-06 Zeneca Ltd Pyrrolidine derivatives
US5610296A (en) * 1994-12-05 1997-03-11 G. D. Searle & Co. Process for the preparation of amidino phenyl pyrrolidine beta-alanine urea analogs

Also Published As

Publication number Publication date
IS4837A (is) 1998-08-28
NO984470D0 (no) 1998-09-25
US5994344A (en) 1999-11-30
DK0891362T3 (da) 2004-07-12
EA199800773A1 (ru) 1999-06-24
WO1997036903A1 (en) 1997-10-09
JP4118337B2 (ja) 2008-07-16
IL125859A0 (en) 1999-04-11
PE55298A1 (es) 1998-09-19
HUP9900567A3 (en) 2001-02-28
ATE261969T1 (de) 2004-04-15
EP0891362B1 (en) 2004-03-17
AP823A (en) 2000-04-25
EA001437B1 (ru) 2001-02-26
BR9708449A (pt) 1999-08-03
JP2000507950A (ja) 2000-06-27
NZ331490A (en) 2000-06-23
NO984470L (no) 1998-11-25
US6057457A (en) 2000-05-02
CO4790152A1 (es) 1999-05-31
CA2250209A1 (en) 1997-10-09
YU41198A (sh) 1999-09-27
EP0891362A1 (en) 1999-01-20
AU2291797A (en) 1997-10-22
DE69728139T2 (de) 2004-10-21
EE9800335A (et) 1999-04-15
CZ309798A3 (cs) 1999-02-17
AU726649B2 (en) 2000-11-16
DE69728139D1 (de) 2004-04-22
CN1219935A (zh) 1999-06-16
CN1067075C (zh) 2001-06-13
PT891362E (pt) 2004-08-31
ES2217404T3 (es) 2004-11-01
PL329153A1 (en) 1999-03-15
KR20000005039A (ko) 2000-01-25
AR006401A1 (es) 1999-08-25
HUP9900567A2 (hu) 1999-06-28
AP9801351A0 (en) 1998-09-30
TR199801935T2 (xx) 1999-03-22
US6215002B1 (en) 2001-04-10

Similar Documents

Publication Publication Date Title
US6057457A (en) Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase
US5374648A (en) Indole derivatives and pharmaceutical use thereof
DE69411317T2 (de) Indoloylguanidinderivate als Inhibitoren des Natrium-Protonen Austauschs
US20030232832A1 (en) Pyrrolotriazinone compounds and their use to teat diseases
US20030153507A1 (en) HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
JP4607457B2 (ja) ピロロピリミジンA2b選択的アンタゴニスト化合物、それらの合成、及び使用
CA2501947A1 (en) Azaindole derivatives as inhibitors of p38 kinase
IE58788B1 (en) Ethylenediamine monoamide derivatives
US5977136A (en) Tetrahydroquinolines as NMDA antagonists
RU2162470C2 (ru) 2,7-замещенные производные октагидропирроло[1,2-а]пиразина, способ лечения, фармацевтическая композиция, промежуточные соединения
US5962448A (en) Pyrroloazepine derivatives
US5210208A (en) Disubstituted aryl compounds exhibiting selective leukotriene b4 antagonist activity
EP0436157B1 (en) Quinazoline derivatives and their preparation
EP1819332B1 (en) Pyrrolopyridine-2-carboxylic acid amides
EP0557526A1 (en) Pyrroloazepine compound
SK3242000A3 (en) Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase
JPWO1997000258A1 (ja) 三環性ベンゾアゼピン化合物
US6310064B1 (en) Aralkyl diazabicycloalkane derivatives for CNS disorders
EP0008950A2 (en) Pyrimido(1,6-a)indole derivatives and intermediates therefor, processes for their preparation, pharmaceutical compositions containing the derivatives and their use
JP2001515905A (ja) ピロロピロロン誘導体
CZ2000878A3 (cs) Pyrrolopyrrolonové deriváty
HK1107984A1 (en) Pyrrolopyridine-2-carboxylic acid amide derivative useful as inhibitor of glycogen phosphorylase
HK1107984B (en) Pyrrolopyridine-2-carboxylic acid amide derivative useful as inhibitor of glycogen phosphorylase